Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05042609) enrolled 139 participants in total — 90 in the TRS01 group and 49 in the Active Comparator group. The trial was measuring eye inflammation, specifically looking at cells visible in the front part of the eye (called the anterior chamber) as a way to track how inflammation changed over 28 days. The main question the trial asked was how many participants had no detectable inflammation cells by Day 28. The reported data shows that by Day 28, 44 participants in the TRS01 group and 15 in the Active Comparator group had a complete absence of inflammation cells (a score of zero). When a slightly broader measure was used — counting either zero cells or only a trace amount — 52 participants in the TRS01 group and 42 in the Active Comparator group met that threshold at Day 28. For a secondary measure looking at the average change in inflammation score from the start of the trial to Day 28 (on a scale of 0 to 4, where 0 means no inflammation and 4 means severe), the TRS01 group showed an average decrease of 1.9 points, while the Active Comparator group showed an average decrease of 2.2 points. Similar patterns were also reported at Day 21, an earlier check-in point during the trial. The reported data also shows that at Day 21, 32 participants in the TRS01 group and 29 in the Active Comparator group had a complete absence of inflammation cells, while 50 and 40 participants respectively had either zero or trace-level cells. The average change in inflammation score from the start to Day 21 was a decrease of 1.7 points for TRS01 and 2.1 points for the Active Comparator group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41485727) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male or female and up to 75 years old (if the trial site is in the US), or between 18 and 70 years old (if the trial site is in Europe).
- You have been diagnosed with a specific type of active eye inflammation (non-infectious anterior uveitis) with a moderate level of inflammation in one eye, either without current treatment or with stable treatment that needs to be improved.
- You have reasonably good vision (meeting a specific vision test score) in your eye that is not being studied.
Who may not be able to join:
- You are currently pregnant or breastfeeding.
- You have a history of, or currently have, a significant eye disease in either eye.
- You have uncontrolled eye pressure (above a specific level) or a type of glaucoma called narrow angle glaucoma in either eye, or are at risk of a pressure-related eye problem when your pupils are dilated.
- The back of your eye cannot be properly examined due to difficulty dilating your pupils or cloudiness inside the eye.
- You have cancer or melanoma that is currently being treated with a type of therapy that works through the immune system.
- You have certain serious health conditions or diseases affecting the rest of your body (confirm with trial site).
- You are currently taking certain medications or receiving certain treatments as outlined in the study rules (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Anterior Chamber Cell (ACC) Grade = 0 on Day 28; Anterior Chamber Cell (ACC) Grade = 0 or 1 on Day 28
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.